With the significant enhancement of traditional Chinese medicine inheritance and innovation capabilities, applications for clinical trials of new traditional Chinese medicines have also begun to increase in recent years
.
Recently, Jianmin Pharmaceutical Group submitted a clinical application for Tongjiang Granules, which is a new type of Chinese medicine 1.
1 drug
.
It is reported that Jianmin Pharmaceutical Group exclusively acquired Tongjiang Granules preclinical research materials and all technical secrets and patents during the clinical application period owned by Xiyuan Hospital of Chinese Academy of Chinese Medical Sciences in 2018, with a transaction amount of 10 million yuan
.
It is understood that Jianmin Pharmaceutical Group has been actively deploying the Chinese patent medicine gastric medicine market.
At the end of 2021, the company has won a new type of Chinese medicine, Qirui Weishu Capsule, which is used for mild to moderate chronic non-atrophic gastritis with erosion.
Epigastric pain caused by damp-heat stasis syndrome
.
The clinical application of Tongjiang Granules is the company's second class 1 new drug in the Chinese patent medicine stomach medicine market, which is mainly used for the treatment of gastroesophageal reflux disease
.
Regarding the clinical application submitted this time, Jianmin Pharmaceutical Group stated that after the development of Tongjiang Granules is completed, it will fill the gap in the domestic Chinese patent medicine market for the treatment of gastroesophageal reflux disease.
Featured traditional Chinese medicine varieties, enrich the company's product line
.
It is worth noting that, in fact, with the implementation of relevant national policies to promote the development of traditional Chinese medicine and the continuous improvement of technical guidelines, the research and development of new traditional Chinese medicines has entered an accelerated period in recent years, and many traditional Chinese medicine companies have ushered in new breakthroughs in category 1 new drugs.
.
According to the data, as of April this year, there have been 8 new Chinese medicines of Category 1 on the market, namely the anti-tumor drug Icariin Soft Capsule, Qirui Weishu Capsule, the antidepressant Suxia Jieyu Chufan Capsule, and the anti-gout drug.
Huzhen Qingfeng Capsules, Kunxinning Granules for gynecology, Xuanqijiangu Tablets for reducing swelling and pain relief, Qihuang Capsules for diabetes, Yinqiao Qingre Tablets for colds
.
In addition to the above products, incomplete statistics show that there are more than 60 new TCM Class 1 drugs that are in the stages of clinical application, clinical approval, and marketing application
.
Among them, there are Taizi Shenyue Capsules, Naoshang Lesheng Granules, Guangjincao Total Flavonoids Capsules, Xiaoer Lianhuaqinggan Granules, Ginkgolide Dropping Pills,
etc.
At present, under the background of the continuous high enthusiasm for innovation and research and development of traditional Chinese medicine companies, a large number of pharmaceutical companies are still increasing their efforts to deploy new traditional Chinese medicine drugs
.
In addition to Jianmin Pharmaceutical, such as Kangyuan Pharmaceutical has always adhered to innovation-driven development, and invested a large amount of research and development funds every year for product development and technological innovation
.
In 2021, the company's research and development expenses will be 499 million yuan, a year-on-year increase of 31.
27%; in the first half of 2022, the company's research and development expenses will be 277 million yuan, a year-on-year increase of 28.
01%
.
In the first half of 2022, Kangyuan Pharmaceutical also has 1 new Chinese medicine drug application for listing, which is the 3.
1 class classic prescription Lingguizhugan granules; 2 class 1 Chinese medicine new drugs are submitted for clinical application, specifically Zaobai Anshen granules and Busui Yizhi granules.
Zaobai Anshen Granules have been approved for clinical approval; Jinzhen Oral Liquid, Dazhu Hongjingtian Capsules, Cistanche Total Glycosides Capsules and other 3 products have been marketed, and new indications have been approved for clinical approval
.
In addition, Kangyuan Pharmaceutical has 23 new traditional Chinese medicines mainly distributed in the fields of respiratory, gynecology, orthopedics, and cardiovascular and cerebrovascular treatment, which are in the clinical application stage and above
.
Among them, 4 are class 1.
1 new drugs
.
